• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,100.47 109.25
( 0.14%)
Global Indices
Nasdaq
51,927.61 57.71
(0.11%)
Dow Jones
7,374.18 -5.04
(-0.07%)
Hang Seng
72,467.78 3,292.81
(4.76%)
Nikkei 225
10,536.79 75.16
(0.72%)
Forex
USD-INR
94.55 -0.19
(-0.20%)
EUR-INR
107.36 -0.64
(-0.59%)
GBP-INR
124.56 -0.65
(-0.52%)
JPY-INR
0.58 0.00
(-0.30%)

EQUITY - MARKET SCREENER

Bal Pharma Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524824
INE083D01012
65.3864135
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
BALPHARMA
19.72
133.1
EPS(TTM)
Face Value()
Div & Yield %
4.24
10
1.44
 

NBCC gains on securing projects worth over Rs 45 crore
Jun 04,2026

The company received an Rs 39.99 crore order from Canara Bank for the construction of a residential building at Plot No. 624/1617, Shimpoli Road, Borivali West, Mumbai.

Separately, NBCC has been awarded a Rs 5.51 crore PMC contract by the Resident Commissioner, Andhra Pradesh Bhavan, for the upgradation of Bungalow No. 1, Janpath, the official residence of the Chief Minister of Andhra Pradesh.

Both contracts have been awarded by domestic entities and are not related-party transactions.

NBCC (India) operates in three major segments—project management consultancy, real estate, and engineering procurement & construction.

The company’s consolidated net profit jumped 37.22% to Rs 241.38 crore on 1.81% rise in revenue from operations to Rs 4559.79 crore in Q4 FY26 over Q4 FY25.